
Genentech and Roche Break Ground on US Manufacturing Facility
The $700 million project is part of Genentech and Roche’s $50 billion investment in U.S. manufacturing, infrastructure and R&D
The $700 million project is part of Genentech and Roche’s $50 billion investment in U.S. manufacturing, infrastructure and R&D
Genentech, the US biotech arm of Swiss pharma giant Roche, is building a new small-batch biologics manufacturing facility at its Oceanside campus in California, USA. Groundbreaking took place on Feb. 10.
Bowing to growing pressure from activist investors with different missions, the supervisory board of tradition-steeped German pharmaceuticals and agrochemicals player Bayer has announced the appointment of a new CEO to succeed embattled incumbent Werner Baumann — a year before the end of the current chief executive’s regular term.